Related Experiment Videos

[Inhibitory effect of RNA interference on chronic myeloid leukemia bcr/abl oncogene expression]

Xiao-xia Ma1, Chun Wang, Ju Wei

  • 1Department of Hematology, Shanghai First People's Hospital, Shanghai 200080, China.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|September 28, 2005
PubMed
Abstract

Insights

Chemically synthesized small interfering RNAs (siRNAs) effectively inhibited the chronic myeloid leukemia (CML) bcr/abl oncogene. This RNA interference approach reduced cancer cell proliferation and induced apoptosis, offering a novel anti-leukemia strategy.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Context:

  • Chronic myeloid leukemia (CML) is characterized by the BCR-ABL oncogene.
  • Targeting oncogenic drivers is a key strategy in cancer therapy.

Purpose:

  • To investigate the efficacy of RNA interference (RNAi) using small interfering RNAs (siRNAs) to suppress the expression of the BCR-ABL oncogene in CML.
  • To evaluate the impact of BCR-ABL oncogene inhibition on K562 CML cell proliferation and apoptosis.

Summary:

  • In vitro synthesized siRNAs were delivered into K562 cells via electroporation, achieving approximately 70% transfection efficiency.
  • Real-time quantitative RT-PCR and Western blot analyses confirmed significant inhibition of BCR-ABL oncogene expression at both mRNA and protein levels.
  • MTT and Annexin V-FITC assays demonstrated that siRNA treatment reduced K562 cell proliferation by 47-56% and induced apoptosis from 1% to 15-19% over 48 hours.

Impact:

  • RNA interference targeting the BCR-ABL oncogene presents a promising new cellular-level therapeutic strategy for chronic myeloid leukemia.
  • This study validates siRNA as a tool for investigating and potentially treating CML by directly targeting its driving oncogene.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...